Bold claim: Early use of CARVYKTI® can drive durable, treatment-free remissions for relapsed or refractory multiple myeloma, even after just one infusion. Now, let’s dive into what this means, why it matters, and what opinions it might spark.
Johnson & Johnson today shared updated Phase 3 CARTITUDE-4 results supporting lasting treatment-free remissions with CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) when used as early as second-line therapy. In as-treated standard-risk patients who received CARVYKTI® at their first relapse, 80 percent showed no disease progression and did not require further therapy over 30 months (2.5 years). These findings add to a broad clinical and real-world experience across more than 9,000 patients treated with CARVYKTI® worldwide.
Translational analyses indicate that using CARVYKTI® earlier correlates with stronger immune fitness and longer progression-free survival (PFS). In other words, initiating CARVYKTI® earlier may harness a more vigorous immune response, contributing to better long-term outcomes. These observations were highlighted in oral presentations at the 2025 American Society of Hematology (ASH) Annual Meeting (Abstracts #92 and #94).
Luciano J. Costa, M.D., Ph.D., a professor at the University of Alabama and CARTITUDE-4 principal investigator, explained that a single CARVYKTI® infusion for standard-risk patients at first relapse could yield deeper, more durable remissions and move the treatment approach closer to long-term disease control or potential cure. Jordan Schecter, M.D., Johnson & Johnson Innovative Medicine’s VP of R&D for Multiple Myeloma, emphasized CARVYKTI®’s proven efficacy when used early and its distinctive role in extending overall survival versus standard therapies.
In CARTITUDE-4, 176 patients received CARVYKTI® as second-line therapy, with 59 of them having standard-risk cytogenetics. At a median follow-up of about 33.6 months, the 30-month PFS rate for these standard-risk patients plateaued at 80.5% following a single infusion. Notably, among the 26 patients who achieved MRD-negative complete response at 12 months, all remained progression-free at 30 months.
A separate translational analysis examined immune biomarkers linked to PFS in CARTITUDE-1 and CARTITUDE-4. It found that patients treated after one or two prior therapies displayed stronger immune fitness—evidenced by higher baseline CD4+ naive T cells in blood—and an immune-activated bone marrow environment. This suggests that earlier intervention with CARVYKTI® may contribute to longer PFS through immunologic mechanisms.
As CARVYKTI® adoption broadens across academic centers and community practices, Johnson & Johnson continues to collect and analyze clinical and real-world data to better understand long-term remission and safety trends. This growing, diverse dataset helps inform the potential expansion of CARVYKTI® into earlier treatment settings.
About CARTITUDE-1
CARTITUDE-1 is a Phase 1b/2, open-label, multicenter study evaluating cilta-cel in adults with RRMM, most of whom were refractory to the last therapy and triple-class refractory. The trial’s Phase 1b portion established safety and dosing for outpatient administration, guiding subsequent CARTITUDE studies. The Phase 2 portion focused on overall response as the primary endpoint in a heavily pretreated population with historically short PFS and overall survival.
About CARTITUDE-4
CARTITUDE-4 is the first randomized Phase 3 trial comparing CARVYKTI® to standard-of-care regimens (PVd or DPd) in adults with relapsed and lenalidomide-refractory MM who had one to three prior therapies. The primary endpoint is PFS, with several secondary endpoints including safety, overall survival, MRD negativity, and overall response rate.
About CARVYKTI®
CARVYKTI® (cilta-cel) is a BCMA-directed autologous T-cell immunotherapy. It reprograms a patient’s own T-cells to target BCMA-expressing myeloma cells, offering a targeted approach to fighting MM. CARVYKTI® received FDA approval in February 2022 for adults with RRMM after four or more prior lines of therapy and later expanded to include patients with fewer prior lines who are refractory to lenalidomide, with EMA approvals following in 2024.
Safety is a cornerstone of CARVYKTI® use. The product carries warning labels for cytokine release syndrome (CRS), neurologic toxicities (including ICANS and other neurotoxic events), HLH/MAS, prolonged cytopenias, infections, hypogammaglobulinemia, and potential secondary malignancies, among other risks. Management guidelines emphasize readiness with supportive care, tocilizumab, corticosteroids, infection prevention, vaccination considerations, and prolonged monitoring for neurologic and hematologic events. Patients should be educated on recognizing CRS and ICANS symptoms and instructed to seek prompt medical care if they occur.
Safety is balanced with efficacy in clinical practice. In CARTITUDE-1 and CARTITUDE-4, CRS affected a majority of treated patients but was often manageable with timely intervention. Neurologic events, while less common, require vigilance given their potential severity and delayed onset. Lifelong monitoring for cytopenias, infections, and secondary malignancies is advised.
Additional information, including the full prescribing details and label warnings, is available through Janssen and CARVYKTI’s official resources.
Contemporary context for readers: MM remains a challenging, largely incurable disease, with significant ongoing research aimed at extending remission duration and survival. CARVYKTI® represents a foundational shift toward early, immune-based strategies that may redefine treatment trajectories for suitable patients.
Discussion prompts: Do these early-intervention results justify broadening CARVYKTI® use to more patients earlier in the disease course, or should caution prevail until longer-term data mature? How might differing patient populations, risk profiles, or healthcare settings influence the balance of benefits and risks? Share your perspective in the comments: is earlier CARVYKTI® treatment a path to real, durable remission, or are there important caveats to consider?
Source: Johnson & Johnson
